BLOG

What Does Autologous Mean in NK Cell Therapy? A Guide for Patients in Japan

Published 2026.10.06 7 min read

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

If you are reading about NK cell therapy in Japan, you will often see the word autologous. It sounds technical, but the idea is simple, and it explains much of how this treatment is designed. This article explains what autologous means, why it matters, and what it does not mean, so that you can have a more informed conversation with a doctor before making any decision.

The short answer: autologous means your own cells

Autologous means that the cells used in a treatment come from the same person who receives them. In NK cell therapy, a small amount of blood is collected from you through a standard blood draw. Natural killer (NK) cells are then activated and expanded outside the body at a specialized facility, and the cells are returned to you by intravenous infusion.

This is different from allogeneic approaches, in which cells come from a donor. At Grand Green Osaka Umekita Clinic, NK cell therapy is a cancer immune cell therapy built around the patient’s own cells. It is offered as a self-pay treatment, which means it is not covered by public insurance in Japan, and a doctor needs to confirm whether it is appropriate for you.

What are NK cells, and why are they used?

NK cells are a type of lymphocyte that circulates in the blood. They belong to the innate immune system, which means they can recognize and respond to abnormal cells, such as cancer cells and virus-infected cells, without waiting for instructions from other immune cells. This is the origin of the name natural killer.

Researchers describe a process called immune surveillance, in which immune cells including NK cells find and remove abnormal cells before they grow. NK cell activity is known to decline with age, stress, and the effects of cancer itself. The idea behind NK cell therapy is to return a larger number of more active NK cells, with the aim of reinforcing immune function that may have weakened. Published research on NK cell therapies is still developing, and results differ between cancer types and study designs, so it is best not to assume that findings from one study apply to every patient.

Why does using your own cells matter?

The main reason the autologous approach is discussed so often is how the body treats its own cells. Because the returned cells originate from you, the risk of rejection is considered low. Serious side effects have rarely been reported with this kind of therapy, although temporary reactions such as fever or fatigue can occur. Every person responds differently, and a doctor will review your medical history before treatment.

Using your own cells also keeps the physical process relatively simple for the patient. Treatment involves a blood draw and an intravenous infusion, with no hospital stay, so many people are able to continue daily life during treatment. Still, simpler does not mean risk-free. Any treatment involving cell processing and infusion carries possible risks, and these should be discussed in detail at a consultation.

Cells come from your own blood, not from a donor.
The risk of rejection is considered low, but reactions such as temporary fever or fatigue may occur.
The process does not require hospitalization.
Whether it suits your situation is a medical decision made together with a doctor.

What autologous does not mean

It is important to be clear about the limits. Autologous does not mean guaranteed, and it does not mean a cure. NK cell therapy is not a replacement for surgery, chemotherapy, or radiation therapy. Rather, it is described as a therapy that does not interfere with these standard treatments and may be considered alongside them. When you are already receiving standard cancer treatment, the clinic can coordinate with the medical institution that provides it, and your primary oncology team should remain part of every decision.

The activity and number of cells that can be grown also depend on the individual, and the effect of treatment cannot be predicted in advance. Anyone who promises a specific outcome should be approached with caution. A responsible consultation will explain both what the therapy aims to do and what is still uncertain.

How the treatment is overseen in Japan

In Japan, cell-based treatments of this kind are provided under the Act on the Safety of Regenerative Medicine. Under this system, a clinic submits a treatment plan that is reviewed by a certified committee and filed with the Ministry of Health, Labour and Welfare, and cells are processed at a licensed cell processing facility. For international patients, this framework is worth asking about, because it tells you how the treatment is regulated and who is responsible for each step.

Because NK cell therapy is a self-pay treatment, costs, number of sessions, treatment period, risks, and side effects are explained during a consultation rather than assumed from general information. The fee and flow sections of the clinic’s information page are a good starting point, and they can be reviewed before you decide to book.

Questions to bring to a consultation in Osaka

Grand Green Osaka Umekita Clinic is located in Umeda, Osaka, and provides an information page for international patients. If you are considering a consultation, preparing a few questions can make the conversation more useful, especially if you are traveling from another country and have a limited amount of time.

Based on my diagnosis and current treatment, is NK cell therapy a reasonable option to consider?
How will my own cells be collected, processed, and returned, and how long does each step take?
What reactions might I experience, and whom should I contact if they occur?
How will the clinic coordinate with my current oncologist?
What are the total costs, and what is not included?
What are the realistic limits of this therapy for someone in my situation?

Bringing recent medical records and a list of current medications, translated into English if possible, will also help the doctor give you a more accurate explanation.

Summary

Autologous means that NK cells are taken from your own blood, expanded outside the body, and returned to you. This is why the risk of rejection is considered low, and treatment can be done as an outpatient procedure. It does not mean that results are guaranteed, and it is not a substitute for standard cancer treatment. Because the therapy is a self-pay treatment provided under Japan’s regenerative medicine framework, the details of cost, risk, side effects, and suitability should always be confirmed with a doctor at a consultation. Reviewing the clinic’s NK cell therapy page and preparing your questions in advance is a practical way to begin.

Autologous NK Cell Therapy

1ConsultationDoctor reviews your situation
2Blood drawYour own blood
3Activation and expansionAt a licensed facility
4IV infusionCells returned to you

This figure is a conceptual summary of the article content

Learn more about NK Cell Therapy

References

Supervising Physician

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.

Back to article list › Back to NK Cell Therapy ›